Mechanism of the Antibacterial Activity and Resistance of Polymyxins

Matthew D. Johnson,Roger L. Nation,Jian Li
DOI: https://doi.org/10.1007/978-3-319-46718-4_23
2017-01-01
Abstract:Discovered in the 1940s, polymyxins are antimicrobial peptides produced by the Gram-positive soil bacterium, Paenibacillus polymyxa, which biosynthesizes polymyxins using non-ribosomal peptide synthetase enzymes [1–3]. Polymyxin B and E (polymyxin E was originally named colistin but was determined to have an identical structure) were used clinically in the late 1950s against Gram-negative bacterial infections [4, 5]. However, nephrotoxic and neurotoxic effects of polymyxin treatment became evident, causing a decline in the use of the polymyxins in the 1970s [6]. Soon, newer antibiotics, such as the aminoglycosides, replaced polymyxins in the clinic. However, since the early 2000s the emergence of multidrug-resistant (MDR) Gram-negative organisms, combined with a lack of novel antimicrobial agents, has led to the resurgence of interest in polymyxins as a last-line treatment ([7–10]; Nation and Li 2009).
What problem does this paper attempt to address?